RecruitingNCT01706692

Swiss Dermatology Network of Targeted Therapies (SDNTT)

Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics

Sponsor

Swiss Dermatology Network for Targeted Therapies

Enrollment

1,121 participants

Start Date

Feb 1, 2011

Study Type

OBSERVATIONAL

Conditions

Psoriasis

Summary

The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy. The registry will also evaluate safety clinical outcomes and health related quality of life.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist,
age ≥ 18,
Being administered a specific biologic/conventional systemic drug for the first time
Sufficient language skills (German, French, Italian and English) for the informed consent to participate
Informed consent to participate

Exclusion Criteria2

Lack of informed consent
Patients being participants of clinical trials at the day of registration to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analyzed separately)

Interested in this trial?

Get notified about updates and connect with the research team.